Your browser doesn't support javascript.
loading
Intestinal barrier functions in hematologic and oncologic diseases.
Haroun, Elio; Kumar, Prashanth Ashok; Saba, Ludovic; Kassab, Joseph; Ghimire, Krishna; Dutta, Dibyendu; Lim, Seah H.
Afiliação
  • Haroun E; Division of Hematology and Oncology, State University of New York Upstate Medical University, SUNY Upstate Medical University, 750 E Adams, Syracuse, NY, 13210, USA.
  • Kumar PA; Division of Hematology and Oncology, State University of New York Upstate Medical University, SUNY Upstate Medical University, 750 E Adams, Syracuse, NY, 13210, USA.
  • Saba L; Department of Medicine, Saint-Joseph University of Beirut, Beirut, Lebanon.
  • Kassab J; Department of Medicine, Saint-Joseph University of Beirut, Beirut, Lebanon.
  • Ghimire K; Division of Hematology and Oncology, State University of New York Upstate Medical University, SUNY Upstate Medical University, 750 E Adams, Syracuse, NY, 13210, USA.
  • Dutta D; Division of Hematology and Oncology, State University of New York Upstate Medical University, SUNY Upstate Medical University, 750 E Adams, Syracuse, NY, 13210, USA. dibyendudutta12@gmail.com.
  • Lim SH; Division of Hematology and Oncology, State University of New York Upstate Medical University, SUNY Upstate Medical University, 750 E Adams, Syracuse, NY, 13210, USA. seahhlim@yahoo.com.
J Transl Med ; 21(1): 233, 2023 03 31.
Article em En | MEDLINE | ID: mdl-37004099
ABSTRACT
The intestinal barrier is a complex structure that not only regulates the influx of luminal contents into the systemic circulation but is also involved in immune, microbial, and metabolic homeostasis. Evidence implicating disruption in intestinal barrier functions in the development of many systemic diseases, ranging from non-alcoholic steatohepatitis to autism, or systemic complications of intestinal disorders has increased rapidly in recent years, raising the possibility of the intestinal barrier as a potential target for therapeutic intervention to alter the course and mitigate the complications associated with these diseases. In addition to the disease process being associated with a breach in the intestinal barrier functions, patients with hematologic and oncologic diseases are particularly at high risks for the development of increased intestinal permeability, due to the frequent use of broad-spectrum antibiotics and chemoradiation. They also face a distinct challenge of being intermittently severely neutropenic due to treatment of the underlying conditions. In this review, we will discuss how hematologic and oncologic diseases are associated with disruption in the intestinal barrier and highlight the complications associated with an increase in the intestinal permeability. We will explore methods to modulate the complication. To provide a background for our discussion, we will first examine the structure and appraise the methods of evaluation of the intestinal barrier.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Hepatopatia Gordurosa não Alcoólica / Intestinos Limite: Humans Idioma: En Revista: J Transl Med Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Hepatopatia Gordurosa não Alcoólica / Intestinos Limite: Humans Idioma: En Revista: J Transl Med Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos